Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538054 · ClinicalTrials.gov registry record · Phase 2
Dextromethorphan in Fibromyalgia
A Phase 2 study of Fibromyalgia, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT03538054: Completed Phase 2 study of Fibromyalgia, sponsored by University of Alabama at Birmingham.
NCT03538054 is a Phase 2 study of Fibromyalgia that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 27 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538054, a Phase 2 study of Fibromyalgia, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this protocol is to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. DXM is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce FM pain by suppressing inflammation in the central nervous system. The investigators will be observing the effects of DXM on daily self-reported pain measures in people with FM. If DXM reduces FM pain, it will provide important information about the nature of FM pathophysiology.
Primary Outcome
Daily self-reported widespread pain severity, rated on a 0 - 100 scale (0 = no pain and 100 = worst pain possible). Participants' daily scores from the last 4 weeks of each condition (placebo and dextromethorphan) were summed and then averaged across the 4-week time period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dextromethorphan
Study Locations (1)
Alabama
- University of Alabama of Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2020-03-18 |
| Phase | Phase 2 |
What the finished NCT03538054 record still lists
NCT03538054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03538054 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03538054 about?
NCT03538054 is a clinical study titled "Dextromethorphan in Fibromyalgia". The objective of this protocol is to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. DXM is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce FM pain by suppressing inflammation in the central nervous system. The investigators wil...
What is the current status of trial NCT03538054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-06-26. Estimated completion is 2020-03-18.
What conditions does trial NCT03538054 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT03538054?
The interventions under investigation include: Placebo (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT03538054?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03538054 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03538054's enrollment target sits among peer trials
27 62nd of 76 higher than 15 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nitrous Oxide as Treatment for Fibromyalgia
RECRUITING · Phase 2
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
-
Gabapentin in Fibromyalgia Trial (GIFT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI